Who is impact biomedical?

Impact Biomedical Inc. is a subsidiary of DSS, Inc (“DSS”: NYSE). IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.

Who owns impact biomedical?

HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and ... China is one of the leading markets globally for insect repellants China is one of the leading markets globally for insect repellants

Does impact biomedical have a patent for low glycemic sugar?

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc. (NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Lae...